Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer

Metastatic Breast Cancer Clinical Trial

Official title:

A Pilot Study of Sequential ("First Strike, Second Strike") Therapies, Modeled on Evolutionary Dynamics of Anthropocene Extinctions, for Hormone Positive Metastatic Breast Cancer

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06409390
• Other study ID #: MCC-22617
• Status: Recruiting
• Phase: Early Phase 1
• Start date: April 26, 2024
• Est. completion date: April 2027

Study information

• Verified date: June 2024
• Source: H. Lee Moffitt Cancer Center and Research Institute
• Contact: Jennifer Childress
• Phone: 813-745-0578
• Email: jennifer.childress[@]moffitt.org
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to test a treatment strategy with currently approved drugs to see if it is practical to administer the available drugs in a new way that researchers hope could be more effective in treating metastatic breast cancer.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 15
• Est. completion date: April 2027
• Est. primary completion date: April 2027
• Accepts healthy volunteers: No
• Gender: Female
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Female patients 18 years or older

• Histologically or cytologically confirmed diagnosis of hormone positive HER2 negative metastatic breast cancer per ASCO/CAP criteria (Allison et al, 2020, Wolff et al, 2018), with diagnosis established through either a breast/axillary biopsy or biopsy of a metastatic lesion.

• Hormone positive MBC previously treated with endocrine therapy with either an aromatase inhibitor or Tamoxifen (alone or in combination with a CDK4/6 inhibitor).

• Elevated breast tumor markers which may include cancer antigen 15-3 (CA 15-3) levels above the institutional upper limit of normal (ULN) range of 0.0-31.0 U/mL, cancer antigen 27-29 (CA 27-29) (range <38 U/mL) and/or elevated Carcinoembryonic antigen (CEA) above institutional upper limit of normal (range 0.0 - 5.2 ng/mL).

• Presence of measurable disease on imaging via RECIST v1.1.

• ECOG performance status 0-1.

• Participants must have adequate organ and marrow function as defined in the protocol.

• A negative pregnancy test for pre-menopausal women of childbearing potential.

• Pre-menopausal women of childbearing potential who are sexually active with a male partner must agree to use adequate contraception prior to the study, for the duration of study participation.

• Inclusion of minorities: patients of all races and ethnic groups who meet the above inclusion and below exclusion criteria are eligible for this trial.

• Stated willingness to comply with all study procedures and availability for the duration of the study.

• Ability to understand and the willingness to sign a written informed consent document or have a legally authorized representative sign on the participant's behalf.

Exclusion Criteria:

• Have previously received Fulvestrant for treatment of their breast cancer.

• History of allergic reactions attributed to the study drugs.

• Documented brain metastasis or active or newly diagnosed CNS metastases, including meningeal carcinomatosis, because systemic treatment would need to be paused for these patients.

• Treatment with any investigational compound within 30 days prior to the first dose of study drugs or during this study.

• Diagnosis or treatment for another systemic malignancy within 2 years before the first dose of study drugs, or previously diagnosed with another malignancy and have any evidence of residual disease. Patients with non-melanoma skin cancer or carcinoma in situ of any type are not excluded if they have undergone complete resection.

• Uncontrolled intercurrent illness including-but not limited to-ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.

• Patients with advanced, symptomatic visceral spread, that are at risk of life-threatening complications in the short term, including massive uncontrolled effusions (peritoneal, pleural, pericardial), pulmonary lymphangitis.

• Known history of testing positive for human immunodeficiency virus (HIV) or known acquired immunodeficiency syndrome.

• Active infection including tuberculosis, hepatitis B (known positive HBV surface antigen [HBsAg]), or hepatitis C (HCV). Participants with a past or resolved HBV infection (defined as the presence of hepatitis B core antibody [anti-HBc] and absence of HBsAg) are eligible. Participants with positive HCV antibody are eligible if polymerase chain reaction is negative for HCV RNA.

• Concurrent or prior use of immunosuppressive medication within 14 days before the first dose of study drugs, with the following exceptions: premedication with dexamethasone, intranasal, inhaled, topical or local steroid injections, systemic corticosteroids at physiologic doses not exceeding 10 mg/day of prednisone or its equivalent; steroids as premedication for hypersensitivity reactions (e.g., premedication for iodinated contrast allergy before CT scan).

• Inability to comply with protocol requirements.

• Pregnant and/or breastfeeding women are excluded.

Related Conditions & MeSH terms

• Breast Neoplasms
• Metastatic Breast Cancer

Intervention

Drug:
• Taxotere
75 mg/m2 once every 21 days for 4 cycles
• Cytoxan
600 mg/m2 once every 21 days for 4 cycles
• Trastuzumab deruxtecan
5.4 mg/kg once every 21 days for 5 cycles
• Sacituzumab govitecan
10 mg/kg on days 1 and 8 cycled every 21 days for 5 cycles
• Xeloda
1000 mg/m2 orally twice daily for 14 days cycled every 21 days for 5 cycles
• Fulvestrant
500 mg intramuscular (IM) on days 1, 15 and 28 of the first cycle followed by every 28 days for a total of 4 cycles
• Ribociclib
600 mg orally daily 21 days on, 7 days off
• Abemaciclib
150 mg by mouth twice daily

Locations

Country	Name	City	State
United States	Moffitt Cancer Center	Tampa	Florida

Sponsors (1)

Lead Sponsor	Collaborator
H. Lee Moffitt Cancer Center and Research Institute

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Feasibility of Sequential Therapy	The proportion of patients able to complete the sequence of therapies by the conclusion of the trial.	Up to 18 months
Secondary	Safety and Tolerability	The proportion of patients who experience adverse events or serious adverse events.	Up to 18 months
Secondary	No Evidence of Disease (NED)	The proportion of patients who are able to reach NED status by the conclusion of the trial will be calculated.	Up to 18 months